本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Nurix Therapeutics

25.44
-0.0600-0.24%
盤後25.440.00000.00%19:30 EDT
成交量:283.95萬
成交額:7,207.67萬
市值:26.31億
市盈率:-7.46
高:25.80
開:25.32
低:25.01
收:25.50
52周最高:28.23
52周最低:8.20
股本:1.03億
流通股本:9,504.52萬
量比:2.13
換手率:2.99%
股息:- -
股息率:- -
每股收益(TTM):-3.4102
每股收益(LYR):-3.0514
淨資產收益率:-80.30%
總資產收益率:-40.06%
市淨率:6.53
市盈率(LYR):-8.34

資料載入中...

2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/16

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2021/02/16

重要事件披露

8-K - Current report
2021/02/04

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/12/07

重要事件披露

8-K - Current report
2020/10/26

重要事件披露

8-K - Current report
2020/10/14

重要事件披露

8-K - Current report
2020/10/14

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2020/10/14

重要事件披露

8-K - Current report
2020/08/10

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/08/03

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/07/24

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2020/07/23

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2020/07/21

SEC問詢函

CORRESP [Cover] - Correspondence
2020/07/21

SEC問詢函

CORRESP [Cover] - Correspondence
2020/07/20

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2020/07/10

SEC問詢函

CORRESP [Cover] - Correspondence
2020/07/02

招股説明書

S-1 - General form for registration of securities under the Securities Act of 1933